1/47
Looks like no tags are added yet.
pulmonary hypertension general info
increased pressure in the pulmonary arterial circulation either leaving or entering the lungs
due to thickened and stiff pulmonary arteries
overloads right ventricle causing hypertrophy and failure
most common causes of pulmonary hypertension
left heart failure
parenchymal lung disease with hypoxia (COPD)
secondary causes of pulmonary HTN
OSA
pulmonary embolus
connective tissue disorders
pulmonary htn sx
mPAP (mean pulmonary arterial pressure) > 20mmHg at rest via cardiac catheterization
progressive dyspnea on exertion
easy fatigability
atypical chest pain and unexplained syncope
progressive pulmonary HTN sx
right heart failure
chest pain
syncope
palpitations
cough
physical exam findings of pulmonary HTN
JVD
pulmonic ejection click
tricuspid murmur
hepatomegaly
peripheral edema
cor pulmonale: right side heart failure due to chronic lung disease or hypoxemia
PH dx
TTE
right heart catheterization: gold standard
HIV testing, liver enzymes, pulmonary CTA, PFTs, polysomnography, antinuclear antibody testing
RV function is most important predictor of prognosis
PH tx of all WHO groups
diuretics as needed
oxygen as needed
lifestyle recommendations
routine vaccinations
early referral to PH center
lung transplant if medical therapy fails
WHO group 1 general info
disease localized to the pulmonary arteries (pulmonary arterial hypertension)
smooth muscle hypertrophy, structural changes
endothelial dysfunction
causes of WHO group 1 pulmonary arterial HTN
idiopathic
weight loss
drugs
HIV
schistosomiasis (parasites)
congenital heart disease L → R shunt
WHO group 1 pulmonary arterial HTN tx
refer to specialized centers
endothelin receptor antagonist + phosphodiesterase inhibitor
ambrisentan + tadalafil
CC blockers can work after trial during cardiac cath
Who Group 2 general info
pulmonary venous HTN secondary to left heart disease
elevated left atrial and pulmonary venous pressure
most common cause of pulmonary HTN
WHO group 2 pulmonary venous HTN most common causes
left sided HF
valvular heart disease (mitral or aortic)
WHO group 2 sx
increased P2
peripheral edema
dyspnea
fatigue
WHO group 2 pulmonary venous HTN tx
treat underlying valve disease
left heart failure managed w diuretics
WHO group 3 general info
PH due to chronic lung disease or hypoxia
can be obstructive or restrictive
pts with COPD and PH have poorer prognosis, is a progressive disease
WHO group 3 causes
COPD
OSA
interstitial lung disease
pulmonary fibrosis
emphysema
bronchiectasis
WHO group 3 tx
treat underlying lung disease
oxygen therapy in pts with hypoxemia
inhaled treprostinil approved for pts with interstitial lung disease
WHO group 4 general info
thromboembolic hypertension
occlusion of proximal and distal pulmonary arteries
WHO group 4 treatment
anticoagulation
possible thromboendarterectomy for acute pts
WHO group 5 general info
PH related to unclear multifactorial mechanisms
compression of pulmonary vessels due to a tumor or sarcoidosis
blood disorders: polycythemia vera (thick blood)
metabolic disorders: thyroid disease, glycogen storage disease
CKI
WHO group 5 tx
treatment of the underlying condition is key to management
pleural effusion general info
accumulation of excess fluid in the pleural space
caused by cancer, infections, HF
conditions diagnosed via fluid analysis with pleural effusion
malignancy
empyema
TB
fungal infection
chylothorax
urinothorax
esophageal rupture
hemothorax
peritoneal dialysis
causative drugs of pleural effusion
amiodarone
nitrofurantoin
ovarian stimulation therapy
pleural effusion sx
may be asx or cause of chest pain
dyspnea
pleural effusion dx
thoracocentesis with ultrasound guidance
analysis of pleural fluid may slightly treat as well
pleural fluid procedure with a new finding of pleural effusion unless there is an obvious cause (HF, pneumonia)
if fluid analysis fails:
CT, PET, pleural biopsy (mesothelioma)
pleural fluid analysis includes
cell counts
total protein
LDH
glucose
low albumin in transudates
pleural effusion tx
thoracocentesis as necessary
continuous fluid accumulation: chest tube drainage
recurrent cases: pleurodesis
talc to irritate pleural space, causing inflammation and fibrosis
pleural effusion with transudate general info
develops from increased capillary hydrostatic pressure or decreased plasma oncotic pressures in chest
HF, nephrosis, liver failure, hypoalbuminemia
pleural effusion with transudate sx
primarily pale, yellow straw color and clear
bigger molecules can’t get through to the pleural space so there is fluid with less protein concentration
pleural effusion with transudate dx
pleural fluid analysis:
cell counts, total protein, LDH, glucose
low albumin in transudates
pleural effusion from exudate general info
develops from increased vascular permeability or decreased lymphatic resorption secondary to inflammation
etiology of pleural effusion from exudate
empyema infections
lung cancer
lymphoma
hemothorax from trauma
chylothorax
pleural effusion from exudate sx
generally cloudy
if malignant: bloody
if chylothorax: white, milky
confirmed exudate lights criteria
pleural fluid protein/serum ratio > 0.5
fluid LDH/serum ratio >0.6
fluid LDH >2/3 the upper limit of normal for serum LDH
LDH > 1000 IU/L
triglycerides in fluid > 100mg/dL = chylothorax
fluid glucose <60mg/dL: malignancy, TB, empyema
amylase: pancreatitis
nucleated cell counts > 50,000 in empyema
pleural effusion from exudate dx
pleural fluid analysis
cell count
total protein
LDH
glucose
lipid analysis if chylothorax
gram stain and culture if infection
cytology if malignancy
obstructive sleep apnea general info
soft palate of the upper airway collapses during sleep, causing hypopneas or obstructive apneas
most common sleep related breathing disorder
obstructive sleep apnea risk factors
obesity: strongest risk factor
BMI > 40 at risk of obesity hypoventilation syndrome
males
younger black americans
older pts
smoking
supine sleeping
soft tissue abnormalities
pregnancy
OSA sx
respiratory effort - related sleep arousals
daytime fatigue, sleepiness, poor concentration
snoring, restlessness, resuscitative snores, fragmented sleep
nocturnal angina, nocturia, morning headaches
poor neurocognitive performance
OSA complications
higher risk of car accidents
systemic HTN, CAD, cardiac arrhythmias
pulmonary HTN
metabolic syndrome, DM, fatty liver disease
chronic hypoventilation
dyspnea on exertion
OSA dx
PE: crowded oropharyngeal airway, large neck circumference
sleep study: apnea hypopnea index > 5 events/hour + 1 or more related sx
can also have 15 or more events without sx
in lab polysomnography: gold standard
OSA tx
continuous positive airway pressure (CPAP)
lifestyle modifications: avoid alcohol, tobacco, hypnotic meds, weight loss (tirzepatide assisted)
alternatives: mouth guard, upper airway surgery to stiffen soft palate, uvulectomy, tonsillectomy, hypoglossal nerve stimulation
obesity hypoventilation syndrome general info
BMI > 30 + awake alveolar hypoventilation
awake PaCO2 > 45mmHg
male sex is not a risk factor
obesity hypoventilation syndrome associated conditions
right HF
polycythemia
HTN
CHF
insulin resistance
obesity hypoventilation syndrome sx
chronic hypoventilation
90% of pts have OSA
dyspnea on exertion more common
obesity hypoventilation syndrome dx
serum bicarbonate > 27mEq/L suggests chronically hypercapnic
O2 stat < 93%
hypoxemia: PO2 < 70mmHg
CBC
TSH, glucose, lipids
polysomnography: AHI is usually more than 15 events per hour
ECG: RHF
echo: if suspected comorbid heart failure of PH
obesity hypoventilation syndrome tx
CPAP or BiPAP
decreases nocturnal arterial CO2, daytime PaCO2, and daytime sleepiness
weight loss: loose > 100 lbs, bariatric surgery, medication, lifestyle mods
treat comorbidities: COPD, hypothyroid
abstain from alcohol, benzos, opioids
supplemental O2 to CPAP but not as monotherapy
pharmacotherapy is last resort